Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
Researchers reviewed studies of drugs that act on serotonin (so-called serotonergic psychedelics) and MDMA. They found that harms and bad reactions are not clearly defined in these studies and are probably reported less often than they actually happen. Some intense or frightening experiences during treatment might help people heal, but…
This article gives health care professionals a plain overview of psilocybin-assisted psychotherapy. It summarizes how psilocybin and its active form psilocin work in the brain, how the body absorbs and clears them, practical issues for dosing and monitoring, legal and access changes, and safety concerns for medically complex patients. The…
This paper looked across existing studies of psilocybin and found that, when it is given along with psychotherapy or therapy-style support, it looks promising as a treatment for several mental health problems, including cases that did not get better with other treatments. But the authors say the current studies are…
This paper looked at 20 clinical trials to see whether therapies that use psychedelic drugs together with talking therapy can help people who have serious, life‑limiting illnesses. The review found that these therapies often helped with psychological and spiritual problems like anxiety, low mood, and fear of dying. The drugs…
This systematic review looked at clinical studies of psilocybin for adults with major depressive disorder. It combined 6 studies with 319 participants, found that every study reported that psilocybin reduced depressive symptoms, and noted few side effects. Each study included psychological support, and the authors say more and better studies…
